Register Login

Aprea Therapeutics Inc. (APRE)

(85% Positive) Aprea Therapeutics, Inc. (APRE) Announces Enrollment Update for Inhibitor Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 24, 2025, 12:37 p.m.

    📋 Aprea Therapeutics, Inc. (APRE) - Clinical Trial Update

    Filing Date: 2025-10-24

    Accepted: 2025-10-24 08:35:24

    Event Type: Clinical Trial Update

    Event Details:

    Aprea Therapeutics Inc. (APRE) Announces Clinical Trial Update Aprea Therapeutics Inc. (APRE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Inhibitor
    • Clinical Stage: Phase 1
    • Collaboration: CCNE1
    • Updated Timeline: October 24, 2025, September 17, 2025

    🔬 Clinical Development Pipeline (Aprea Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Placebo (aCSF) OTHER Phase PHASE1 Parkinson's Disease ClinicalTrials.gov
    LY3962681 DRUG Phase PHASE1 Parkinson's Disease ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Aprea Therapeutics Inc.
    • CIK: 0001781983
    • Ticker Symbol: APRE
    • Period End Date: 2025-10-24
    • Document Type: 8-K

Search

News categories